Document:

Exhibit 10.2

 

THE REGISTERED HOLDER OF THIS UNIT PURCHASE OPTION
BY ITS ACCEPTANCE HEREOF, AGREES THAT THE SECURITIES EVIDENCED BY THIS UNIT PURCHASE OPTION MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED EXCEPT
AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS UNIT PURCHASE OPTION AGREES THAT THE SECURITIES EVIDENCED BY THIS UNIT PURCHASE OPTION
WILL NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED, OR BE THE SUBJECT OF ANY HEDGING, SHORT SALE, DERIVATIVE, PUT, OR CALL
TRANSACTION THAT WOULD RESULT IN THE EFFECTIVE ECONOMIC DISPOSITION OF THIS UNIT PURCHASE OPTION OR THE SECURITIES EVIDENCED BY THIS UNIT
PURCHASE OPTION, FOR A PERIOD OF ONE HUNDRED EIGHTY (180) DAYS FOLLOWING THE EFFECTIVE DATE (DEFINED BELOW) TO ANYONE OTHER THAN TO ANY
MEMBER PARTICIPATING IN THE OFFERING AND THE OFFICERS OR PARTNERS THEREOF, IF ALL SECURITIES SO TRANSFERRED REMAIN SUBJECT TO THE LOCK-UP
RESTRICTION SET FORTH ABOVE FOR THE REMAINDER OF THE TIME PERIOD.

 

UNIT PURCHASE OPTION

 

FOR THE PURCHASE OF [●] UNITS

 

OF ADITXT, INC.

 

1. Unit Purchase Option.

 

THIS CERTIFIES THAT, in consideration
of $100.00 duly paid by or on behalf of [  ] (“Holder”), as registered owner of this Unit Purchase Option, to Aditxt,
Inc. (the “Company”), Holder is entitled, at any time or from time to time commencing on the 180th day after the
effective date (the “Effective Date”) of the registration statement (the “Registration Statement”) pursuant to
which certain units of securities are offered for sale to the public (the “Offering”) (the “Commencement Date”),
and at or before 5:00 p.m., Eastern Time, on the fifth anniversary of the Effective Date (the “Expiration Date”), but not
thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●]1 units
(the “Units”) of the Company, each Unit consisting of one share of the Company’s common stock, par value $0.001 per
share (the “Shares”) and one Series C warrant to purchase one Share (the “Warrant(s)”). Each Warrant is the same
as the warrants included in the Units being registered for sale to the public (the “Public Warrants”) under the Securities
Act of 1933, as amended (the “Act”), provided that the Holder shall not be entitled to utilize the cashless exchange provision
set forth in Section 2.2.7(b) of the Series C warrant. If the Expiration Date is a day on which banking institutions are authorized
by law to close, then this Unit Purchase Option may be exercised on the next succeeding day which is not such a day in accordance with
the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the
Unit Purchase Option. This Unit Purchase Option is initially exercisable at $12.395 per Unit so purchased; provided, however, that upon
the occurrence of any of the events specified in Section 5 hereof, the rights granted by this Unit Purchase Option, including the exercise
price per Unit and the number of Units to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise
Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context.

 

 

		1	[Insert 5.0% of units]

 

    -1-

     

    

 

2. Exercise.

 

(a) Exercise Procedure. In
order to exercise this Unit Purchase Option, the exercise form attached hereto must be duly executed and completed and delivered to the
Company, together with this Unit Purchase Option and payment of the Exercise Price for the Units being purchased payable in cash or by
certified check or official bank check. If the subscription rights represented hereby shall not be exercised at or before 5:00 p.m., Eastern
time, on the Expiration Date, this Unit Purchase Option shall become and be void without further force or effect, and all rights represented
hereby shall cease and expire.

 

(b) Legend. If required by
applicable law at the time of any exercise, each certificate for the securities purchased under this Unit Purchase Option shall bear a
legend as follows unless such securities have been registered under the Act:

   

“THE SECURITIES REPRESENTED
BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) OR APPLICABLE STATE
LAW. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE ACT AND APPLICABLE STATE LAW.”

 

(c) Cashless Exercise.

 

(i) In lieu of the payment
of the Exercise Price multiplied by the number of Units for which this Unit Purchase Option is exercisable (and in lieu of being entitled
to receive Shares and Warrants) in the manner required by Section 2(a), the Holder shall have the right (but not the obligation) to convert
any exercisable but unexercised portion of this Unit Purchase Option into Units consisting of Shares and Warrants (the “Conversion
Right”) as follows:

 

(A) Upon exercise of the Conversion
Right, the Company shall deliver to the Holder (without payment by the Holder of any of the Exercise Price in cash) that number of Shares
equal to the quotient obtained by dividing (x) the Value of the portion of the Unit Purchase Option being converted by (y) the Current
Market Price of a Share.

 

(B) The “Value”
of the portion of the Unit Purchase Option being converted shall equal the remainder derived by subtracting (a) (i) the Exercise Price
multiplied by (ii) the number of Units underlying the portion of this Unit Purchase Option being converted, from (b) the Current Market
Value of a Unit multiplied by the number of Units underlying the portion of the Unit Purchase Option being converted.

 

(C) As used herein, the term
“Current Market Value” per Unit at any date means the remainder derived by subtracting (x) the exercise price of the Warrants
multiplied by the number of Shares issuable upon exercise of the Warrants underlying one Unit from (y) the Current Market Price of the
Shares multiplied by the number of Shares included within one Unit and underlying the Warrants included within one Unit.

 

    -2-

     

    

 

(D) The “Current Market
Price” of a Share shall mean (i) if the Shares are listed on a national securities exchange or quoted on the OTCQB or OTCQX (or
any successor exchange or entity), the closing or last sale price of the Shares in the principal trading market for the Shares on the
last trading day preceding the day in question as reported by the exchange, the OTCQB or OTCQX, as the case may be; (ii) if the Shares
are not listed on a national securities exchange or quoted on the OTCQB or OTCQX, but are traded in the residual over-the-counter market,
the closing bid price for the Shares on the last trading day preceding the date in question for which such quotations are reported in
the “Pink Sheets” published by OTC Markets Group, Inc. or similar publisher of such quotations; and (iii) if the fair market
value of the Shares cannot be determined pursuant to clause (i) or (ii) above, such price as the Board of Directors of the Company shall
determine, in good faith.

 

(ii) The Cashless Exercise
Right may be exercised by the Holder on any business day on or after the Commencement Date and not later than the Expiration Date by delivering
the Unit Purchase Option with the duly executed exercise form attached hereto with the cashless exercise section completed to the Company,
exercising the Cashless Exercise Right and specifying the total number of Units the Holder will purchase pursuant to such Cashless Exercise
Right.

 

(d) Resale of Shares. Holder
and the Company acknowledge that as of the date hereof the Staff of the Division of Corporation Finance of the SEC has published Compliance
& Disclosure Interpretation 528.04 in the Securities Act Rules section thereof, stating that the holder of securities issued in connection
with a public offering may not rely upon Rule 144 promulgated under the Act to establish an exemption from registration requirements under
Section 4(a)(1) under the Act, but may nonetheless apply Rule 144 constructively for the resale of such shares in the following manner:
(a) provided that six months has elapsed since the last sale under the registration statement, an underwriter or finder may resell the
securities in accordance with the provisions of Rule 144(c), (e), and (f), except for the notice requirement; (b) a purchaser of the shares
from an underwriter receives restricted securities unless the sale is made with an appropriate, current prospectus, or unless the sale
is made pursuant to the conditions contained in (a) above; (c) a purchaser of the shares from an underwriter who receives restricted securities
may include the underwriter’s holding period, provided that the underwriter or finder is not an affiliate of the issuer; and (d)
if an underwriter transfers the shares to its employees, the employees may tack the firm’s holding period for purposes of Rule 144(d),
but they must aggregate sales of the distributed shares with those of other employees, as well as those of the underwriter or finder,
for a six-month period from the date of the transfer to the employees. Holder and the Company also acknowledge that the Staff of the Division
of Corporation Finance of the SEC has advised in various no-action letters that the holding period associated with securities issued without
registration to a service provider commences upon the completion of the services, which the Company agrees and acknowledges shall be the
closing of the Offering, and that Rule 144(d)(3)(ii) provides that securities acquired from the issuer solely in exchange for other securities
of the same issuer shall be deemed to have been acquired at the same time as the securities surrendered for conversion (which the Company
agrees is the date of the initial issuance of this Unit Purchase Option). In the event that following a request by Holder to transfer
the Shares in accordance with Compliance & Disclosure Interpretation 528.04 counsel for the Company reasonably concludes that Compliance
& Disclosure Interpretation 528.04 no longer may be relied upon as a result of changes in applicable laws, regulations, or interpretations
of the SEC Division of Corporation Finance, or as a result of judicial interpretations not known by the Company or its counsel on the
date hereof (either, a “Registration Trigger Event”), then the Company shall promptly, and in any event within five (5) business
days following the request, provide written notice to Holder of such determination. As a condition to giving such notice, the Company
shall offer Holder a single “piggyback” registration right pursuant to an agreement in form reasonably acceptable to the Holder;
provided that notwithstanding anything to the contrary, the obligations of the Company pursuant to this Section 2 shall terminate on the
fifth anniversary of the effective date of the Registration Statement pursuant to which the Offering is being made. In the absence of
such conclusion by counsel for the Company, the Company shall, upon request of Holder given no earlier than six months after the final
closing of the Offering, instruct its transfer agent to permit the transfer of such shares in accordance with Compliance & Disclosure
Interpretation 528.04, provided that Holder has provided such documentation as shall be reasonably be requested by the Company to establish
compliance with the conditions of Compliance & Disclosure Interpretation 528.04. Notwithstanding anything to the contrary, pursuant
to FINRA Rule 5110(f)(2)(G)(iv), the Holder shall not be entitled to more than one “piggyback” registration right hereunder
and the duration of the registration rights hereunder shall not exceed five years from the Effective Date.

 

    -3-

     

    

 

3. Transfer.

 

(a) Restrictions—General. The
securities evidenced by this Unit Purchase Option shall not be sold, transferred, assigned, pledged or hypothecated, or be the subject
of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of, this Unit
Purchase Option (or any securities underlying this Unit Purchase Option) for a period of one hundred eighty (180) days following the Effective
Date to anyone other than to any member participating in the offering and the officers or partners thereof, if all securities so transferred
remain subject to the lock-up restriction set forth above for the remainder of the time period. In order to make any permitted assignment,
the Holder must deliver to the Company the assignment form attached hereto duly executed and completed, together with the Unit Purchase
Option and payment of all transfer taxes, if any, payable in connection therewith. The Company shall within three business days transfer
this Unit Purchase Option on the books of the Company and shall execute and deliver a new Unit Purchase Option or Unit Purchase Options
of like tenor to the appropriate assignee(s) expressly evidencing the right to purchase the aggregate number of Units purchasable hereunder
or such portion of such number as shall be contemplated by any such assignment.

 

(b) Restrictions—Securities. The
securities evidenced by this Unit Purchase Option shall not be transferred unless and until (i) the Company has received the opinion of
counsel for the Holder that the securities may be transferred pursuant to an exemption from registration under the Act and applicable
state securities laws, the availability of which is established to the reasonable satisfaction of the Company, or (ii) a registration
statement or a post-effective amendment to the Registration Statement relating to such securities has been filed by the Company and declared
effective by the Securities and Exchange Commission (the “Commission”) and compliance with applicable state securities law
has been established.

 

4. New Unit Purchase Options to be Issued.

 

(a) Partial Exercise. Subject
to the restrictions in Section 3 hereof, this Unit Purchase Option may be exercised or assigned in whole or in part. In the event of the
exercise or assignment hereof in part only, upon surrender of this Unit Purchase Option for cancellation, together with the duly executed
exercise or assignment form and funds sufficient to pay any Exercise Price, the Company shall cause to be delivered to the Holder without
charge a new Unit Purchase Option of like tenor to this Unit Purchase Option in the name of the Holder evidencing the right of the Holder
to purchase the number of Units purchasable hereunder as to which this Unit Purchase Option has not been exercised or assigned.

 

(b) Loss, Theft, Destruction. Upon
receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of this Unit Purchase Option and of
reasonably satisfactory indemnification or the posting of a bond, the Company shall execute and deliver a new Unit Purchase Option of
like tenor and date. Any such new Unit Purchase Option executed and delivered as a result of such loss, theft, mutilation or destruction
shall constitute a substitute contractual obligation on the part of the Company.

 

5. Adjustments.

 

(a) Exercise Price
and Number of Securities. The Exercise Price and the number of Units underlying the Unit Purchase Option shall be subject to adjustment
from time to time as hereinafter set forth:

 

(i) If after the date hereof,
and subject to the provisions of Section 5(c) below, the number of outstanding Shares is increased by a stock dividend payable in Shares
or by a split-up of Shares or other similar event, then, on the effective date thereof, the number of Shares underlying each of the Units
purchasable hereunder shall be increased in proportion to such increase in outstanding shares. In such case, the number of Shares, and
the exercise price applicable thereto, underlying the Warrants underlying each of the Units purchasable hereunder shall be adjusted in
accordance with the terms of the Warrants. For example, if the Company declares a two-for-one stock dividend and immediately prior to
such dividend this Unit Purchase Option is for the purchase of one Unit at $10.00 per whole Unit (with each Warrant underlying the Units
being exercisable for $12.00 per share), upon effectiveness of the dividend, this Unit Purchase Option will be adjusted to allow for the
purchase of one Unit at $10.00 per Unit, each Unit entitling the holder to receive two Shares and two Warrants (each Warrant exercisable
for $6.00 per share).

 

    -4-

     

    

 

(ii) If after the date hereof,
and subject to the provisions of Section 5(c), the number of outstanding Shares is decreased by a consolidation, combination or reclassification
of the Shares or other similar event, then, on the effective date thereof, the number of Shares underlying each of the Units purchasable
hereunder shall be decreased in proportion to such decrease in outstanding shares. In such case, the number of Shares, and the exercise
price applicable thereto, issuable upon exercise of the Warrants included in each of the Units purchasable hereunder shall be adjusted
in accordance with the terms of the Warrants. For example, if the Company effects a one-for-two stock reverse stock split and immediately
prior to such stock split this Unit Purchase Option is for the purchase of one Unit at $10.00 per whole Unit (with each Warrant underlying
the Units being exercisable for $12.00 per share), upon effectiveness of the stock split, this Unit Purchase Option will be adjusted to
allow for the purchase of one Unit at $10.00 per Unit, each Unit entitling the holder to receive 0.5 Shares and 0.5 Warrants (each Warrant
exercisable for $24.00 per share).

 

(iii) In case of any reclassification
or reorganization of the outstanding Shares other than a change covered by Section 5(a)(i) or 5(a)(ii) hereof or that solely affects the
par value of such Shares, or in the case of any merger or consolidation of the Company with or into another corporation (other than a
consolidation or merger in which the Company is the continuing corporation and that does not result in any reclassification or reorganization
of the outstanding Shares), or in the case of any sale or conveyance to another corporation or entity of the property of the Company as
an entirety or substantially as an entirety in connection with which the Company is dissolved, the Holder of this Unit Purchase Option
shall have the right thereafter (until the expiration of the right of exercise of this Unit Purchase Option) to receive upon the exercise
hereof, for the same aggregate Exercise Price payable hereunder immediately prior to such event plus the aggregate exercise price of the
Shares underlying the Warrants immediately prior to such event, the kind and amount of shares of stock or other securities or property
(including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution following any such
sale or transfer, by a Holder of the number of Shares of the Company obtainable upon exercise of this Unit Purchase Option and the underlying
Warrants immediately prior to such event; and if any reclassification also results in a change in Shares covered by Section 5(a)(i) or
5(a)(ii), then such adjustment shall be made pursuant to Sections 5(a)(i) or 5(a)(ii) and this Section 5(a)(iii). The provisions of this
Section 5(a)(iii) shall similarly apply to successive reclassifications, reorganizations, mergers or consolidations, sales or other transfers.

 

(iv) This form of Unit Purchase
Option need not be changed because of any change pursuant to this Section 5, and Unit Purchase Options issued after such change may state
the same Exercise Price and the same number of Units as are stated in the Unit Purchase Options initially issued pursuant to this Agreement.
The acceptance by any Holder of the issuance of new Unit Purchase Options reflecting a required or permissive change shall not be deemed
to waive any rights to an adjustment occurring after the Commencement Date or the computation thereof.

 

(b) Substitute Unit
Purchase Option. In case of any consolidation of the Company with, or merger of the Company with, or merger of the Company into,
another corporation (other than a consolidation or merger which does not result in any reclassification or change of the outstanding Shares),
the corporation formed by such consolidation or merger shall execute and deliver to the Holder a supplemental Unit Purchase Option providing
that the holder of each Unit Purchase Option then outstanding or to be outstanding shall have the right thereafter (until the stated expiration
of such Unit Purchase Option) to receive, upon exercise of such Unit Purchase Option, the kind and amount of shares of stock and other
securities and property receivable upon such consolidation or merger, by a holder of the number of Shares of the Company for which such
Unit Purchase Option might have been exercised immediately prior to such consolidation, merger, sale or transfer. Such supplemental Unit
Purchase Option shall provide for adjustments which shall be identical to the adjustments provided in this Section 5. The above provision
of this Section 5 shall similarly apply to successive consolidations or mergers.

 

    -5-

     

    

 

(c) Fractional Interests. The
Company shall not be required to issue certificates representing fractions of Shares or Warrants upon the exercise of the Unit Purchase
Option, nor shall it be required to issue scrip or pay cash in lieu of any fractional interests, it being the intent of the parties that
all fractional interests shall be eliminated by rounding any fraction up to the nearest whole number of Warrants, Shares or other securities,
properties or rights.

 

6. Reservation and Listing. The Company
shall at all times reserve and keep available out of its authorized Shares, solely for the purpose of issuance upon exercise of the Warrants
underlying the Unit Purchase Option, such number of Shares or other securities, properties or rights as shall be issuable upon the conversion
or exercise thereof. The Company further covenants and agrees that upon exercise of the Warrants underlying the Unit Purchase Option and
payment of the respective Warrant exercise price therefor, all Shares and other securities issuable upon such exercise shall be duly and
validly issued, fully paid and non-assessable and not subject to preemptive rights of any stockholder. As long as the Unit Purchase Option
shall be outstanding, the Company shall use its best efforts to cause all Shares underlying the Unit Purchase Option (including the Shares
issuable upon exercise of the Warrants included in the Units issuable upon exercise of the Unit Purchase Option) to be listed (subject
to official notice of issuance) on all securities exchanges (or, if applicable on the OTC Bulletin Board or any successor trading market)
on which the Shares issued to the public in connection with the Offering may then be listed and/or quoted.

 

7. Certain Notice Requirements.

 

(a) Right to Notice. Nothing
herein shall be construed as conferring upon the Holders the right to vote or consent as a stockholder for the election of directors or
any other matter, or as having any rights whatsoever as a stockholder of the Company. If, however, at any time prior to the expiration
of the Unit Purchase Option and its exercise, any of the events described in Section 7(b) shall occur, then, in one or more of said events,
the Company shall give written notice of such event at least fifteen days prior to the date fixed as a record date or the date of closing
the transfer books for the determination of the stockholders entitled to such dividend, distribution, conversion or exchange of securities
or subscription rights, or entitled to vote on such proposed dissolution, liquidation, winding up or sale. Such notice shall specify such
record date or the date of the closing of the transfer books, as the case may be. Notwithstanding the foregoing, the Company shall deliver
to each Holder a copy of each notice given to the other stockholders of the Company with respect to the events enumerated in Section 7(b)
at the same time and in the same manner that such notice is given to all stockholders, even if less than fifteen days.

 

(b) Enumerated Events. The
Company shall be required to give the notice described in this Section 7 upon one or more of the following events: (i) if the Company
shall take a record of the holders of its Shares for the purpose of entitling them to receive a dividend or distribution payable otherwise
than in cash, or a cash dividend or distribution payable otherwise than out of retained earnings, as indicated by the accounting treatment
of such dividend or distribution on the books of the Company, or (ii) the Company shall offer to all the holders of its Shares any additional
shares of capital stock of the Company or securities convertible into or exchangeable for shares of capital stock of the Company, or any
option, right or warrant to subscribe therefor, or (iii) a dissolution, liquidation or winding up of the Company (other than in connection
with a consolidation or merger) or a sale of all or substantially all of its property, assets and business shall be proposed.

 

    -6-

     

    

 

(c) Change in Exercise
Price. The Company shall, promptly after an event requiring a change in the Exercise Price pursuant to Section 5 hereof, send
notice to the Holders of such event and change (the “Price Notice”). The Price Notice shall describe the event causing the
change and the method of calculating same and shall be certified as being true and accurate by the Company’s President and Chief
Financial Officer.

 

(d) Notice Delivery. All
notices, requests, consents and other communications under this Unit Purchase Option shall be in writing and shall be deemed to have been
duly made when hand delivered, or mailed by express mail or private courier service: (i) If to the registered Holder of the Unit Purchase
Option, to the address of such Holder as shown on the books of the Company, or (ii) If to the Company, to the following address or to
such other address as the Company may designate by notice to the Holders:

 

Aditxt, Inc.

737 N. Fifth Street

Suite 200

Richmond, VA 23219

Attn: Chief Executive Officer

 

with a copy to (which shall not constitute notice):

 

Sheppard, Mullin, Richter & Hampton LLP

30 Rockefeller Plaza

New York, NY 10112

Attn: Richard A. Friedman

 

8. Reserved.

 

9. Miscellaneous.

 

(a) Amendments. The
Company and Dawson James Securities, Inc. (“Dawson”) may, by means of a signed written instrument, from time to time supplement
or amend this Unit Purchase Option without the approval of any of the Holders in order to cure any ambiguity, to correct or supplement
any provision contained herein that may be defective or inconsistent with any other provisions herein, or to make any other provisions
in regard to matters or questions arising hereunder that the Company and Dawson may deem necessary or desirable and that the Company and
Dawson deem shall not adversely affect the interest of the Holders. All other modifications or amendments shall require the written consent
of and be signed by the party against whom enforcement of the modification or amendment is sought.

 

(b) Headings. The
headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning or
interpretation of any of the terms or provisions of this Unit Purchase Option.

 

    -7-

     

    

 

(c) Entire Agreement. This
Unit Purchase Option (together with the other agreements and documents being delivered pursuant to or in connection with this Unit Purchase
Option) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof, and supersedes all prior agreements
and understandings of the parties, oral and written, with respect to the subject matter hereof.

 

(d) Binding Effect. This
Unit Purchase Option shall inure solely to the benefit of, and shall be binding upon, the Holder and the Company and their permitted assignees,
respective successors, legal representative and assigns, and no other person shall have or be construed to have any legal or equitable
right, remedy or claim under or in respect of or by virtue of this Unit Purchase Option or any provisions herein contained.

 

(e) Governing Law. This
Unit Purchase Option shall be governed by and construed and enforced in accordance with the laws of the State of New York, without giving
effect to conflict of laws. The Company hereby agrees that any action, proceeding or claim against it arising out of, or relating in any
way to this Unit Purchase Option shall be brought and enforced in the courts of the State of New York or of the United States of America
for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company
hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Any process or summons
to be served upon the Company may be served by transmitting a copy thereof by registered or certified mail, return receipt requested,
postage prepaid, addressed to it at the address set forth in Section 7 hereof. Such mailing shall be deemed personal service and shall
be legal and binding upon the Company in any action, proceeding or claim. The Company and the Holder agree that the prevailing party(ies)
in any such action shall be entitled to recover from the other party(ies) all of its reasonable attorneys’ fees and expenses relating
to such action or proceeding and/or incurred in connection with the preparation therefor.

 

(f) Waivers. The
failure of the Company or the Holder to at any time enforce any of the provisions of this Unit Purchase Option shall not be deemed or
construed to be a waiver of any such provision, nor to in any way affect the validity of this Unit Purchase Option or any provision hereof
or the right of the Company or any Holder to thereafter enforce each and every provision of this Unit Purchase Option. No waiver of any
breach, non-compliance or non-fulfillment of any of the provisions of this Unit Purchase Option shall be effective unless set forth in
a written instrument executed by the party or parties against whom or which enforcement of such waiver is sought; and no waiver of any
such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance
or non-fulfillment.

 

(g) Counterparts. This
Unit Purchase Option may be executed in one or more counterparts, and by the different parties hereto in separate counterparts, each of
which shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement, and shall become
effective when one or more counterparts has been signed by each of the parties hereto and delivered to each of the other parties hereto.
Such counterparts may be delivered by facsimile transmission or other electronic transmission.

 

(h) Exchange Agreement. As
a condition of the Holder’s receipt and acceptance of this Unit Purchase Option, Holder agrees that, at any time prior to the complete
exercise of this Unit Purchase Option by Holder, if the Company and Dawson enter into an agreement (the “Exchange Agreement”)
pursuant to which they agree that all outstanding Unit Purchase Options will be exchanged for securities or cash or a combination of both,
then Holder shall agree to such exchange and become a party to the Exchange Agreement.

 

[Balance of page intentionally left blank]

 

    -8-

     

    

 

IN WITNESS WHEREOF, the Company
has caused this Unit Purchase Option to be signed by its duly authorized officer as of the [●] day of [●], 2022.

 

	 	Aditxt, Inc.
	 	 	 
	 	By:	 
	 	Name:	Amro Albanna
	 	Title:	Chief Executive Officer

 

    -9-

     

    

 

Form To Be Used To Exercise Unit Purchase
Option

 

Aditxt, Inc.

737 N. Fifth Street

Suite 200

Richmmond, VA 23219

 

Attn: Chief Executive Officer

 

Date:        , 2022

 

The undersigned hereby elects irrevocably to exercise
all or a portion of the within Unit Purchase Option and to purchase      Units of Aditxt, Inc., and hereby
makes payment of $      (at the rate of $      per Unit) in payment of the
Exercise Price pursuant thereto. Please issue the Shares and Warrants comprising the Units as to which this Unit Purchase Option is exercised
in accordance with the instructions given below.

 

or

 

The undersigned hereby elects
irrevocably to convert its right to purchase Units purchasable under the within Unit Purchase Option by surrender of the unexercised portion
of the attached Unit Purchase Option (with a “Value” based of $      based on a “Market
Price” of $      ). Please issue the securities comprising the Units as to which this Unit Purchase
Option is exercised in accordance with the instructions given below.

 

INSTRUCTIONS FOR REGISTRATION OF SECURITIES

 

	Name:	 	 
	 	(Print in Block Letters)	 
	 	 	 
	Address:	 	 

 

NOTICE: THE SIGNATURE TO THIS
FORM MUST CORRESPOND WITH THE NAME AS WRITTEN UPON THE FACE OF THE WITHIN UNIT PURCHASE OPTION IN EVERY PARTICULAR WITHOUT ALTERATION
OR ENLARGEMENT OR ANY CHANGE WHATSOEVER, AND MUST BE GUARANTEED BY A BANK, OTHER THAN A SAVINGS BANK, OR BY A TRUST COMPANY OR BY A FIRM
HAVING MEMBERSHIP ON A REGISTERED NATIONAL SECURITIES EXCHANGE.

 

    -10-

     

    

 

Form To Be Used To Assign Unit Purchase Option

 

ASSIGNMENT

 

(To be executed by the registered Holder to effect
a transfer of the within Unit Purchase Option)

 

FOR VALUE RECEIVED, does hereby sell, assign and
transfer unto the right to purchase Units of Aditxt, Inc., (the “Company”) evidenced by the within Unit Purchase Option and
does hereby authorize the Company to transfer such right on the books of the Company.

 

Dated:     , 2022

 

	 	 
	 	Signature
	 	 
	 	 

 

NOTICE: THE SIGNATURE TO THIS
FORM MUST CORRESPOND WITH THE NAME AS WRITTEN UPON THE FACE OF THE WITHIN UNIT PURCHASE OPTION IN EVERY PARTICULAR WITHOUT ALTERATION
OR ENLARGEMENT OR ANY CHANGE WHATSOEVER, AND MUST BE GUARANTEED BY A BANK, OTHER THAN A SAVINGS BANK, OR BY A TRUST COMPANY OR BY A FIRM
HAVING MEMBERSHIP ON A REGISTERED NATIONAL SECURITIES EXCHANGE.

 

 

-11-EX-10.14

 Exhibit 10.14 

PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K, CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN REDACTED AND, WHERE
APPLICABLE, HAVE BEEN BRACKETED. SUCH REDACTIONS ARE IMMATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 TRI-PARTY AGREEMENT 
 This Tri-Party Agreement (this
“Agreement”) is made by and among Crown Bioscience (Taichang), Inc. (中美冠科生物技术(太仓)有限公司), a PRC limited liability company
(“Licensor”), CB Therapeutics Inc., a Cayman company (“Licensee”), and Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
(正大天晴药业集团L殳份看限公司), a PRC company limited by shares (“CTTQ”) (each of Licensor, Licensee, and CTTQ, a “Party” and
collectively, the “Parties”). 
 RECITALS 

WHEREAS, Licensor has been granted certain license rights pursuant to a humanized anti-PD-L1
mAbanti-cancer drug technology development agreement dated
[                        ] by and between CTTQ and Licensor (the “Primary License Agreement”; a copy of which is attached hereto as Exhibit A); and 

WHEREAS, pursuant to a data sublicense agreement dated
[                        ] by and between Licensor and Licensee (the “SublicenseAgreement”; a
copy of which is attached hereto as Exhibit B), Licensee has been granted an exclusive sublicense under Licensor’s Data Rights provided for by and subject to the Primary License Agreement. 

NOW, THEREFORE, for good and valuable consideration and in consideration of the mutual covenants and agreements set forth herein, the Parties
agree as follow: 
 AGREEMENT 

1. Confirmation of Validity of the Sublicense License Agreement 

1.1 Subject to the limitations set forth in Section 1.2-1.5 below, each Party acknowledges the
existence and validity of the Sublicense Agreement and acknowledges and consents that all terms and conditions, covenants and undertakings set forth in the Sublicense Agreement shall remain in full force and effect, in each case as applicable to
Licensor as a licensee under the Primary License Agreement. This Agreement does not and shall not constitute an amendment to, or waiver of any right or remedy provided in the Sublicense Agreement, 

1.2 This Agreement does not and shall not constitute an amendment to, or waiver of any right or remedy provided in Primary License Agreement,

 1.3 Any conflict exist between the Sublicense Agreement and the Primary License Agreement, or between this Agreement and the Primary
License Agreement, the Primary License Agreement shall be the privilege and final interpretation shall be based on the Primary License Agreement. 

1.4 The Licensor guarantee that (i) in any situation the sublicensing grant to Licensee does not and shall not in violation of the
applicable terms of the Primary License Agreement, (ii) in any situation the terms in the Sublicense Agreement are not conflicted to and shall complies with the applicable terms of the Primary License Agreement, in otherwise the Licensor shall
take the whole responsibility. 

 1.5 The Licensor acknowledges and consents that (i) in the situation the Licensee does
not or could not execute the obligation regarding to the Sublicense Agreement or this Agreement, or the Licensee violates the obligation as a successor of Licensor according to the Primary License Agreement, and (ii) Licensor itself does not or
could not make Licensee execute the obligation as a successor of Licensor regarding to the Primary License Agreement or this Agreement, Licensor shall take the whole responsibility; Licensee shall reimburse and compensate Licensor for any and all
damages and loss suffered by Licensor for undertaking such responsibility as listed in this Section 1.5(i) and (ii). 
 2.
Development and Commercialization of the Licensed Product in the Sublicensed Territory 
 For the purposes of development and
Commercialization of the Licensed Product in the Sublicensed Territory, CTTQ hereby agrees and covenants to provide data, materials directly to Licensee that Licensee may reasonably request, instead of directly to Licensor, precondition are that
(i) hereby ‘reasonably request’ means in scope and extent not beyond terms in the Primary License Agreement and (ii) Licensee acknowledges, consents and comply with conditions regarding to terms of Article 2.2, 2.5(6), 3.1 6.1,
and 10 of the Primary License Agreement. If there are any data or materials that Licensee may request but is not in above scope or extent, CTTQ may in good faith and by its own decision to provide with a mutual signed agreement. CTTQ and Licensee
including its affiliates hereby agree and covenants to collaborate in good faith during and only for purpose of development of the Licensed Product in each territory, including, providing data and materials, entering into a pharmacovigilance
agreement and providing other support and cooperation that each party may reasonably request by one party and be agreed by the other party, 
 Licensee
shall agree and covenants to entering into a manufacturing agreement with CTTQ for CTTQ to manufacture and provide sample of the Licensed Product for purpose of Licensee’s filing of IND and for clinical trials in its territory in good faith.
Only if CTTQ agrees in written Licensee waiving to enter into such manufacturing agreement, Licensee may search for a third party in its territory for such manufacturing agreement, but shall not search for a third party in CTTQ territory in any
time. 
 3. License Grant. 

4. CTTQ hereby grants to Licensee, effective upon any early termination of the Primary License Agreement, the same right, title and
interest as it has granted to Licensor under the terminated Primary License Agreement. Representations and Warranties. 
 Each Party
represents and warrants to the other Parties that it has been duly authorized to execute and deliver this Agreement to the other Parties and the execution and delivery of this Agreement by such Party constitute a valid and binding obligation on such
Party, enforceable against such Party in accordance with its terms, except where such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally. 

 5. Duration and Termination 

5.1 Term. This Agreement commences on the date hereof signature and, unless earlier terminated as provided in this
Section 5, will continue in full force and effect until (i) terminated by written consent of Licensor, CTTQ and Licensee, (ii) terminated by Licensee for convenience as 5.2, or (iii) termination of the Primary License Agreement,
which is earlier. 
 5.2 Termination for Convenience. Licensee may terminate this Agreement for convenience upon [                        ] written notice to Licensor and CTTQ. 
 5.3 Effect of Termination. Termination or
expiration of this Agreement will not relieve the Parties of obligations accruing prior to such termination or expiration. After the date of termination or expiration, Licensee (or any of its affiliates or sublicensees, as applicable) may
(a) sell the Licensed Products then in its stock, and (b) complete the production of the Licensed Products then in the process of production and sell the same. 

6. Infringement 

6.1 Notification; Cooperation. All Parties agree to notify each other of any possible or actual infringement of any Data Rights
relating to the Licensed Product (“Infringement”) of which it becomes aware. Licensor and CTTQ each agrees to use their respective best efforts to enforce the Data Rights with respect to any such Infringement. Licensee agrees to
cooperate fully with Licensor and CTTQ in any action controlled by Licensor and/or CTTQ to enforce the Data Rights with respect to such Infringement. 

6.2 Declaratory Judgment. If a declaratory judgment action is brought naming Licensee as a defendant and alleging invalidity or
unenforceability of any Data Rights, Licensee will promptly notify Licensor and CTTQ in writing and the Parties will discuss in good faith the defense of the invalidity or unenforceability aspect of the action. The Parties will each bear its own
expense in such discussion and defense. 
 7. General Provisions 

7.1 Governing Law; Venue. This Agreement will be governed by, and construed and interpreted in accordance with, the laws of
People’s Republic of China and the State of California, the USA, as applicable(without giving effect to the laws, rules, or principles thereof regarding conflict of laws); provided, however, that all questions with respect to
validity of any patent will be determined in accordance with the laws of the respective country or region in which such patent will have been granted or filed, as applicable. Each Party hereby irrevocably submits itself to and consents to the
exclusive jurisdiction of courts in People’s Republic of China and the State of California, the USA, as applicable for the purposes of any claim, suit or proceeding in connection with any controversy, claim or dispute arising out of or relating
to this Agreement. 
 7.2 Equitable Relief. Each Party acknowledges that its breach of this Agreement may cause irreparable
injury to the other Party for which monetary damages may not be an adequate remedy. Therefore, each Party shall be entitled to seek injunction, specific performance, and other appropriate equitable relief to prevent or curtail any actual or
threatened breach of the obligations by the other Party. The rights and remedies provided to each Party in this Section 7.2 are cumulative and in addition to any other rights and remedies available to such Party at law or in equity. 

 7.3 Relationship of Parties. Nothing contained in this Agreement will be
deemed or construed as creating a joint venture, agency, employment or fiduciary relationship among the Parties. No Party nor their respective agents have any authority of any kind to bind the other Parties in any respect whatsoever, and the
relationship among the Parties is, and at all times will continue to be, that of independent contractors. 
 7.4 Assignment and
Successors. This Agreement may not be assigned by any Party without the prior written consent of the other Parties, which will not be unreasonably withheld, except that Licensee’s bankruptcy trustee may assume this Agreement in bankruptcy
of Licensee and each Party may assign this Agreement to a successor in connection with any merger, consolidation, reorganization or sale of all or substantially all of its assets or that portion of its business to which this Agreement relates;
provided, however, that any permitted assignee agrees in writing in a manner reasonably satisfactory to all Parties to be bound by the terms of this Agreement. Any assignment purported or attempted to be made in violation of the terms
of this Section will be null and void and of no legal effect. 
 7.5 Further Assurances. Each Party agrees to take or cause to
be taken such further actions, and to execute, deliver and file or cause to be executed, delivered and filed such further documents and instruments, and to obtain such consents, as may be reasonably required or requested in order to effectuate fully
the purposes, terms and conditions of this Agreement. If a Party is unable, after making reasonable inquiry, to secure the signature of the other Party on the foregoing documents or instruments or obtain from the other Party the foregoing consents,
then such other Party hereby irrevocably designates and appoints the inquiring Party and its duly authorized officers and agents as the other Party’s agent and
attorney-in-fact solely for the purpose of acting for and in its behalf and stead to execute and file any such documents or instruments and to do all other lawfully
permitted acts in furtherance of the foregoing. 
 7.6 Amendment. This Agreement may be amended, modified, superseded or
canceled, and any of the terms may be waived, only in a written instrument signed by Licensor, CTTQ, and Licensee, or, in the case of waiver, in a written instrument signed by the Party waiving compliance. The delay or failure of any Party at any
time or times to require performance of any provisions hereof will in no manner affect the rights at a later time to enforce the same. 

7.7 Waiver. A waiver, express or implied, by any Party hereto, of any right under this Agreement, of any failure to perform, or
of the breach hereof, by any other Party hereto, will not constitute or be deemed to be a waiver of any other right hereunder or of any other failure to perform or breach hereof by such other Party, whether of a similar or dissimilar nature thereto.

 7.8 Capitalized Terms and Headings. Except as otherwise expressly set forth herein, capitalized terms used but not otherwise
defined herein shall have the meanings ascribed to them in the Sublicense Agreement, in each case as applicable to Licensor as a licensee under the Primary License Agreement. Headings are inserted for convenience only and will not affect the
construction of this Agreement. 

 7.9 Interpretation. Each Party hereto acknowledges and agrees that:
(a) it and/or its counsel reviewed and negotiated the terms and provisions of this Agreement and has contributed to its revision; (b) the rule of construction to the effect that any ambiguities are resolved against the drafting Party will
not be employed in the interpretation of this Agreement; and (c) the terms and provisions of this Agreement will be construed fairly as to all Parties hereto and not in favor of or against any Party, regardless of which Party was generally
responsible for the preparation of this Agreement. 
 7.10 Severability. If any provision of this Agreement is unenforceable or
invalid under any applicable law or is so held by applicable court decision, such unenforceability or invalidity will not render this Agreement unenforceable or invalid as a whole, and, in such event, such provision will be changed and interpreted
so as to best accomplish the objectives of the Parties within the limits of applicable law or applicable court decision. 
 7.11
Entire Agreement. This Agreement constitutes the entire understanding and only agreement between the Parties with respect to the subject matter hereof and supersedes any and all prior or contemporaneous negotiations, representations,
agreements, and understandings, written or oral, that the Parties may have reached with respect to the subject matter hereof. 
 7.12
English Language. Although this Agreement is written in both English and Chinese, the Chinese language is mere translation and for reference only, and shall not be an official version of this Agreement. Only the English version shall be the
executed and official version of this Agreement. In the event of any conflict in interpretation between the English version and the Chinese translation, the English version shall control. 

7.13 Counterparts. This Agreement may be signed in multiple number of counterparts, each of which will be deemed to be an
original, with the same effect as if the signatures thereto and hereto were upon the same instrument. Signatures to this Agreement transmitted by facsimile transmission, by electronic mail in PDF form, or by any other electronic means designed to
preserve the original graphic and pictorial appearance of a document, will be deemed to have the same effect as physical delivery of the paper document bearing the original signatures. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their
duly authorized representatives as of the date latest written herein:. 
 Crown Bioscience (Taichang), Inc.
(中美冠科生 CB Therapeutics Inc. 

物技术(太仓)有限公司) 

 

							
	By:	 	 /s/ Bing Zim
	  	By:	  	 /s/ SANJEEV REDKAR

	Name:	 	Bing Zim	  	Name:	  	SANJEEV REDKAR
	Title:	 	Ceo	  	Title:	  	PRESIDENT & CEO
	Date:	 	10 Feb 2017	  	Date:	  	FEBRUARY 10, 2017
	Company chop:	  	
	

	  	

  

			
	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.(正大天晴药业集团股份有限公司)
		
	By:	 	 

	Name:	 	
	Title:	 	
	Date:	 	

	Company chop:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]